For the time being, explicit examination of NSCLC tissue samples already require the analysis of activating mutations in EGFR, BRAF, and KRAS proto‐oncogene, GTPase (KRAS) genes, testing for rearrangements in ALK, ROS1, RET, and neurotrophic receptor tyrosine kinases (NTRK1/2/3), the detection of MET exon 14 skipping mutations, and the assessment of Programmed cell death 1‐ligand 1 (PD‐L1) expression. Here, MET is linked to non-small cell lung carcinoma.